Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118298) titled 'A Multicenter, Randomized, Controlled, Open-label, Phase II Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Treatment of Advanced Melanoma' on Feb. 4.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Beijing Cancer Hospital (Peking University Cancer Hospital)

Condition: Melanoma

Intervention: Control group:Comparator drugs include dacarbazine, temozolomide, paclitaxel, and carboplatin/cisplatin. They can be used as monotherapy or in combination chemother

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-02-09

Target Sa...